

p13^{suc1} of *Schizosaccharomyces pombe* Regulates Two Distinct Forms of the Mitotic cdc2 Kinase

GABRIELE BASI† AND GIULIO DRAETTA*

Differentiation Programme, European Molecular Biology Laboratory, 69012 Heidelberg, Germany

Received 5 July 1994/Returned for modification 28 November 1994/Accepted 10 January 1995

***suc1* is an essential gene initially identified for its ability to rescue certain temperature-sensitive alleles of *cdc2* in *Schizosaccharomyces pombe*. The role of *suc1* in the regulation of the *cdc2* kinase is not well understood. In our study, we have characterized the biochemical effect of loss of *suc1* function on specific *cdc2*-cyclin complexes. We show that the *cig1* cyclin is associated with *cdc2* and that the *cdc2*-*cig1* kinase is activated at mitosis, with kinetics similar to those of the *cdc2*-*cdc13* kinase. We provide evidence that loss of *suc1* function affects the kinase activity of the two distinct mitotic forms of the *cdc2* kinase. We also show that a dramatic increase in the level of the *cdc13* protein is associated with loss of *suc1*. These results suggest that mitosis cannot be properly completed in the absence of *suc1*, possibly because of an increase in the level of *cdc2*-*cdc13* complex, and support the idea of a role for *suc1* in the regulation of multiple forms of the *cdc2* kinase.**

The *cdc2* protein kinase is a key regulator of the eukaryotic cell cycle. In the yeasts *Saccharomyces pombe* and *Saccharomyces cerevisiae*, the *cdc2/CDC28* gene is required for progression through the cell cycle at two transition points, in G₁ before Start and later in the cell cycle at the onset of mitosis (34, 36). Increasing evidence indicates that in higher eukaryotes, cell cycle transitions are regulated by a family of *cdc2*-like kinases, the cyclin-dependent kinases (37, 44). Cyclins are proteins which activate the cdk subunits at different phases of the cell cycle. The *cdc2* kinase is activated at mitosis by B-type cyclins. In *S. cerevisiae*, four different cyclins (CLB1 to -4) which activate Cdc28 at mitosis have been identified. Two of these cyclins also function earlier in the cell cycle (18, 39). Other cyclins which function in S phase (16, 43) and in G₁ (20, 40) are known. In fission yeast species, three different B-type cyclin genes have been reported, *cdc13* (5, 21), *cig1* (9), and *cig2* (10). *cdc13* is an essential gene, required for entry into mitosis (5). *cig1* and *cig2* are not essential and are required in late mitosis for nuclear separation (11). A role for *cig1* and *cig2* during the G₁/S transition has also been suggested (9, 11; however, see reference 9 erratum). *cdc2* also associates with a smaller subunit encoded by the *suc1* gene (8, 12). *suc1* was identified as a gene capable of rescuing some temperature-sensitive alleles of *cdc2* in fission yeast species (23, 24). Homologous genes in *S. cerevisiae* and higher eukaryotes have been identified (19, 41). However, despite the experimental efforts, a clear picture has not emerged concerning the function of *suc1*. Experiments with *Xenopus* extracts have suggested an inhibitory role for *suc1* in the tyrosine dephosphorylation of *cdc2*. Addition of 2 μM *suc1* to *Xenopus* oocyte extracts can effectively inhibit entry into M phase, as monitored by nuclear disassembly (15), *cdc2* tyrosine dephosphorylation, and kinase activation (14). The *suc1* inhibitory effect can be counteracted by the addition of *cdc25* to the cell-free system (27). Consistent with an inhibitory effect of *suc1* at the onset of mitosis, in *S. pombe*, *suc1* overexpression causes a delay of the cell cycle (23) or a cell cycle block in G₂ (2), depending on the levels of expression.

Microinjection experiments with mammalian cells have indicated an inhibitory role for *suc1* in mitosis (38). However, microinjection of *suc1* causes the formation of multiple micronuclei rather than simply inhibiting entry into mitosis, an effect that is quite difficult to interpret. In *S. pombe*, after germination of *suc1*-disruptant spores, cell growth is arrested, with condensed chromosomes, mitotic spindles, and a threefold increase in the total histone H1 kinase activity (32). For *S. cerevisiae*, studies performed with strains carrying temperature-sensitive alleles of *cks1* (the budding yeast *suc1* homolog), indicate that Cks1 is required at the G₁/S and the G₂/M transition points (45).

In our study, we have investigated the effect of loss of *suc1* function in a fission yeast strain expressing *suc1* under the control of a thiamine-conditional promoter. We demonstrate the existence of two distinct *cdc2*-cyclin complexes active at mitosis, and we show that the loss of *suc1* function affects the activity of both complexes. Our data support the idea that *suc1* is required for M-phase progression and indicate that *suc1* is involved in the regulation of multiple forms of the *cdc2* kinase.

MATERIALS AND METHODS

Growth of *S. pombe* cells and molecular genetic techniques. The strains used were wild-type 972 (*h*^{-S}), Sp202 (*h*^{-S} *leu1-32*), temperature-sensitive mutants Sp25 (*h*^{-S} *cdc10-129*), Sp26 (*h*^{-S} *cdc13-117*), Sp27 (*h*^{-S} *cdc1-7*), Sp28 (*h*^{-S} *cdc6-23*), Sp29 (*h*^{+N} *cdc20-M10*), Sp30 (*h*^{+N} *cdc22-M45*), Sp31 (*h*^{+N} *cdc17-K42*), Sp32 (*h*^{-S} *cdc25-22*), and Sp33 (*h*^{+N} *cdc21-M68*) and the cold-sensitive strain *h*^{-S} *nda3-KM311* (26). For the construction of the *suc1*-conditional strain, the integrative plasmid pRIP89-*suc1*, carrying a modified version of promoter *nmt1* (*nmt1-T89* [4, 31]) was transformed in the diploid strain PN536 (*h*⁻/*h*⁺ *suc1*⁺/*suc1*⁺; *suc1*Δ*ura4*⁺ *leu1-32/leu1-32 ura4-D18/ura4-D18*), a generous gift of J. Hayles (23). After sporulation of the transformants and digestion of the vegetative cells with Glusulase (DuPont), spores were plated in thiamine-free minimal medium and incubated until colonies formed. Colonies were replica plated in minimal medium with or without 4 μM thiamine and were screened for the ability to grow in the absence but not in the presence of thiamine. One such colony of each type was selected for further studies. Integration of the plasmid was verified by the plasmid instability test (1). For experiments involving induction of the *nmt1* promoter, cells were grown in minimal medium (33) with or without 4 μM thiamine. The concentration of thiamine used in experiments involving repression of the *nmt1-T89* promoter was 10 μM. For all the other experiments, the medium used was, unless otherwise indicated, YEA (3% glucose, 0.5% yeast extract, 75 mg of adenine per liter). The temperature for growth was 30°C, except for temperature- and cold-sensitive strains, which were grown at 25 and 36°C, respectively. Transformation of *S. pombe* was carried out by the lithium acetate procedure (33).

Flow cytometry and microscopy. Cells were fixed in 70% ethanol, stained with

* Corresponding author. Present address: Mitotix, 1 Kendall Sq., Bldg. 600, Cambridge, MA 02139. Phone: (617) 225-0001. Fax: (617) 225-0005.

† Present address: Department of Genetics, Harvard Medical School, Boston, MA 02115.

propidium iodide, and analyzed by using a FACScan flow cytometer (Becton Dickinson), as described in reference 42. 4',6-Diamidino-2-phenylindole (DAPI) staining was carried out as described in reference 30. Phase-contrast and fluorescence micrographs were obtained with a Zeiss Axioskop microscope.

***S. pombe* extract preparation.** For preparation of *S. pombe* cell extracts, 5×10^9 exponentially growing cells were collected by centrifugation and pooled in a single Eppendorf tube. After centrifugation and aspiration of the supernatant, 250 μ l of lysis buffer (50 mM Tris-HCl [pH 8], 250 mM NaCl, 50 mM sodium fluoride, 5 mM EDTA, 0.1 mM sodium orthovanadate, 0.1% Triton X-100, 1 mM dithiothreitol) containing protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride, 1 μ g of leupeptin per ml, 10 μ g of tolylsulfonyl phenylalanyl chloromethyl ketone [TPCK] per ml, 10 μ g of tosyl-llysine chloromethyl ketone [TLCK] per ml, 1 μ g of aprotinin per ml, and 10 μ g of soybean trypsin inhibitor per ml) were added to the cell pellet. Cell breakage was obtained by vortexing the mixture for 5 min at 4°C in the presence of 500 μ l of glass beads. After centrifugation for 3 min at 13,000 rpm in an Eppendorf Microfuge at 4°C, the soluble fraction was transferred into a new Eppendorf tube and then was centrifuged twice for 15 min at 4°C. The protein concentration of the supernatant was determined by the Bradford assay (7).

Antibody production and purification. The preparation of the anti-*suc1* and G8 (anti-Spcdc2) antisera has been previously described (8, 13). The anti-*cdc13* antiserum was generated by injecting rabbits with the peptide MTTRRLTRQHLLANT corresponding to the amino terminus of *cdc13* (5). The anti-*cig1* antiserum was generated by injecting rabbits with the peptide MDVSTQTRHA-TYFQDEN corresponding to the amino terminus of *cig1* (9). The G3 antiserum was prepared against the peptide CNYLRDFH corresponding to the carboxy terminus of *S. pombe cdc2* (25). The peptides were coupled to the keyhole limpet hemocyanin by methods described in reference 22. Rabbits were injected with 200 μ g of keyhole limpet hemocyanin-peptide conjugate mixed with complete Freund's adjuvant. Subsequently, they were injected with the same amount of protein in incomplete Freund's adjuvant at 4-week intervals until significant immunoreactivity was detected. For affinity purification of the G3 antibodies, 11 mg of the peptide CNYLRDFH was covalently coupled to 2 g of CNBr-activated Sepharose 4B (Pharmacia) according to the instructions of the manufacturer. Twenty milliliters of immune serum was incubated batchwise with 6 ml of the peptide CNYLRDFH coupled to Sepharose and 20 ml of lysis buffer. After overnight incubation at 4°C in a rotator, the Sepharose was poured into a column and washed with 40 ml of lysis buffer and 20 ml of the same buffer containing 1.5 M NaCl. Ten milliliters of glycine-HCl (pH 2.3) in 1-ml aliquots was applied to elute the antibodies. To neutralize the acidic pH, 36 μ l of 1 M Tris (pH 8.8) was added to each 1-ml fraction.

Immunoprecipitations and immunodepletions. Immunoprecipitations were performed by addition of 5 μ l of antiserum to 1 ml of protein extract (0.5 mg/ml for kinase assays and 5 mg/ml for Western blots [immunoblots], unless otherwise indicated) and incubation for 1 h at 4°C. For peptide competition experiments, 25 μ M peptide was added during this incubation. After centrifugation for 3 min at 13,000 rpm in a Microfuge, the soluble fraction was transferred to an Eppendorf tube containing 30 μ l of protein A-Sepharose, vortexed briefly, and incubated for 30 min at 4°C in a rotator. The beads were then washed three times with cold lysis buffer. Proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on acrylamide gradient gel (7.5 to 17.5% for experiments involving *suc1* immunodetection and 10 to 15% for experiments involving *cig1* immunodetection) and were transferred to nitrocellulose membranes by semidry blotting (Millipore) as described in reference 22. For immunodepletions, 50 μ l of protein A-Sepharose was coupled to the antiserum or preimmune serum for at least 1 h, and the beads were washed two times with lysis buffer. Extracts were incubated three times with the prepared immunoprecipitates for 1 h at 4°C on a rotator and were recovered after centrifugation for 10 s in a Microfuge.

Histone H1 kinase assays. For kinase assays, immunoprecipitations were carried out as described above. After the immunoprecipitations, pellets were washed once in kinase assay buffer (50 mM Tris-HCl [pH 7.5], 10 mM MgCl₂, 1 mM dithiothreitol) and were incubated at 30°C in the presence of 40 μ l of kinase assay buffer containing 40 μ M ATP, 25 μ Ci of [γ -³²P]ATP, and 0.2 mg of histone H1 per ml, for 10 min. Samples were analyzed by SDS-12.5% PAGE, and the phosphorylated histone H1 was quantified with a Beckman scintillation counter.

In vitro translation of *cig1*. In vitro transcription and translation of *S. pombe cig1* cloned in the pT7F1A vector (28) were performed with the TnT T7 Coupled Reticulocyte Lysate System (Promega) in accordance with the instructions of the manufacturer.

PAP treatment of *cig1*. Anti-*cig1* immunoprecipitates were incubated at 25°C for 1 h with potato acid phosphatase (PAP, Boehringer; 0.1 U/100 μ l) in 0.1 M sodium-PIPES [piperazine-*N,N'*-bis(2-ethanesulfonic acid); pH 6.0] buffer with or without phosphatase inhibitors (100 mM NaF, 3 mM Na₂MoO₄, 10 mM β -glycerophosphate, 25 mM *p*-nitrophenyl phosphate [pNPP], and 3 mM NaVO₄). The control sample was incubated in the same buffer in the absence of PAP and protease inhibitors.




FIG. 1. Characterization of the *suc1*-conditional strain. Population growth curves of a wild-type (wt) strain and of the *suc1*-conditional strain are shown. Cells were grown in minimal medium at 30°C. At time zero, 10 μ M thiamine was added to the medium. Serial dilution of the cells was used in order to count exponentially growing cells ($<10^7$ cells per ml) during the experiment. The number of cells at each point was calculated with a hemocytometer; that number was then multiplied by the factor of dilution used at time zero. (Inset) Levels of *cdc2* and *suc1* proteins in the wild-type and *suc1*-conditional strains. Equal amounts of total protein extracts (100 μ g) were resolved by SDS-PAGE. After transfer by semidry blotting to a nitrocellulose membrane, the filter was probed with affinity-purified anti-*cdc2* antibodies (α cdc2; upper blot) or with anti-*suc1* polyclonal antiserum (α suc1; lower blot). Lane 1, *suc1*-conditional strain grown in thiamine-free medium. Lanes 2 and 3, wild-type strain (lane 2) and *suc1*-conditional strain (sc) (lane 3) grown for 24 h in minimal medium containing 10 μ M thiamine. Lane 4, bacterially expressed *cdc2* and *suc1*. M, markers.

RESULTS

Construction of a *suc1* thiamine-conditional strain. An *S. pombe* diploid strain heterozygous for *suc1* disruption (see Materials and Methods) was transformed in minimal medium with a plasmid carrying the *suc1* gene downstream of a weak thiamine-repressible promoter (4). Diploid transformants were sporulated under conditions of nitrogen starvation. After germination in minimal medium, spores disrupted for endogenous *suc1* and containing the RIP89-*suc1* vector gave rise to colonies that were replicated in medium supplemented with thiamine. As judged by microscopic examination, addition of thiamine to the medium caused a change in cellular morphology which became fully evident after 24 h of incubation. Several different colonies showed a similar behavior. A representative isolate was selected for further studies and is referred to herein as the *suc1*-conditional strain. The growth kinetics of this strain were followed during a time course of 33 h after the addition of thiamine to the medium (Fig. 1). The generation time of a wild-type strain in minimal medium, at 30°C, is about 3 h. The generation time for the *suc1*-conditional strain grown in the absence of thiamine was similar to that for the wild type. After thiamine addition, cells continued to divide during the first 24 h and then growth was arrested. The block persisted over time, and the cells were completely unable to form colonies when plated in medium containing thiamine. The inset panels of Fig. 1 show an immunoblot of *cdc2* and *suc1* from extracts of wild-type and *suc1*-conditional cells grown in the absence (lane 1) or presence (lanes 2 and 3) of thiamine. While similar amounts of *cdc2* were detected in all extracts, *suc1* was undetectable upon promoter repression by thiamine. Fluorocytometric analysis revealed that growth of cells lacking *suc1* was arrested with a G₂ DNA content (data not shown). Coincident with the cell cycle arrest after 24 h, a change in cell




FIG. 2. Loss of *suc1* function causes a block of cell cycle progression which is associated with chromosome condensation. (A to C) Phase-contrast micrographs of a wild-type strain (A) grown for 24 h in minimal medium with 10 μ M thiamine and of the *suc1*-conditional strain grown for 24 h in minimal medium with (C) or without (B) 10 μ M thiamine. (D to F) Fluorescence micrographs of DAPI-stained cells of the wild-type strain grown for 24 h in minimal medium with 10 μ M thiamine (D) and of the *suc1*-conditional strain grown for 24 h in minimal medium with (F) or without (E) 10 μ M thiamine.

morphology consisting of a heterogeneous elongation of the *suc1*-conditional cells was observed (Fig. 2A to C). The phenotype of the cells was further characterized by DAPI staining (Fig. 2D to F). Under permissive conditions, the *suc1*-conditional strain produced staining similar to that of the wild type,

and spherical or hemispherical nuclei were clearly visible (Fig. 2D and E). In contrast, after *suc1* repression the conditional strain showed nuclei with heterogeneous morphology. Most of the cells showed condensed chromatin, and in some instances individual chromosomes were visible (Fig. 2F). The septum




FIG. 3. High *cdc2* kinase activity level associated with loss of *suc1* function. Cells were grown as described in the legend for Fig. 2. Cell extracts were subjected to anti-*cdc13* (α -*cdc13*) (A) or anti-*cdc2* (α -*cdc2*) (B) immunoprecipitations and assayed for histone H1 kinase activity. Reaction products were analyzed by SDS-PAGE and autoradiography (bottom panel) and were quantified by scintillation counting. sc, *suc1*-conditional strain; wt, wild type.

was present in only some cells. Although at later time points most cells became very elongated, some cells did not elongate and others became misshapen or swollen (not shown). These results, obtained in cycling cells, are in agreement with a previous study performed on spores disruptant for *suc1*. When such spores were germinated, after two or three rounds of cell division, cells were arrested with a heterogeneous morphology and several cells showed condensed chromosomes and a mitotic spindle (32).

Effect of loss of *suc1* function on the *cdc2* kinase. We investigated the effect of loss of *suc1* function on the *cdc2* kinase. The *cdc2*-*cdc13* histone H1 kinase activity was measured after immunoprecipitation of *cdc2* or *cdc13*. Extracts were prepared from a wild-type strain or from the *suc1*-conditional strain grown under permissive or restrictive conditions (Fig. 3). In the *suc1*-conditional strain grown under restrictive conditions, the mitotic *cdc2*-*cdc13* kinase activity was found to be increased by




FIG. 4. An increase of the *cdc13*-*cdc2* complex is associated with loss of *suc1* function. (A) Immunoblots of cells grown for 24 h in minimal medium with (+) or without (-) 10 μ M thiamine. Anti-*cdc13* immunoprecipitates were separated by SDS-PAGE and transferred by semidry blotting to nitrocellulose membranes. The filter was probed with anti-*cdc13* polyclonal antiserum (top blot) or with anti-*cdc2* affinity-purified antibodies (bottom blot). Lane 1, markers (M) (bacterially expressed *cdc13* and *cdc2*); lane 2, *suc1*-conditional strain grown in thiamine-free medium; lanes 3 and 4, wild-type (wt) strain (lane 3) and *suc1*-conditional strain (lane 4) grown for 24 h in minimal medium containing 10 μ M thiamine. sc, *suc1*-conditional strain. (B and C) Time courses for anti-*suc1* (B) and anti-*cdc13* (C) precipitations of extracts prepared 0, 16, 24, and 30 h after thiamine addition. Samples were subjected to immunoblot analysis, and the levels of *suc1* and *cdc13* were quantified by autoradiographic scanning. The strain used in these experiments is described in the text.

approximately 15-fold (Fig. 3A) and the total *cdc2* kinase activity was increased by approximately 6-fold (Fig. 3B) over wild-type levels.

Loss of *suc1* function has no effect on the levels of *cdc2* protein (Fig. 1, top inset panel). To investigate the effect of *suc1* loss on the levels of *cdc13* protein, *cdc13* was immunoprecipitated from an extract of the *suc1*-conditional strain grown for 24 h in the presence of thiamine (Fig. 4A). The level of *cdc13* in the *suc1*-conditional strain was dramatically in-




FIG. 5. Immunoblotting of the *cig1* protein. (A) The Sp202 (*leu1-32*) strain transformed with the pREP1-*cig1* plasmid was grown in minimal medium with (+) or without (-) 4 μ M thiamine for 16 h. Total extracts or immunoprecipitations (IP) were analyzed by SDS-PAGE and transferred by semidry blotting to nitrocellulose membranes. The filter was probed with anti-*cig1* antiserum (α cig1; upper blot) or with anti-*cdc2* affinity-purified antibodies (α cdc2; bottom blot). Lanes 1 and 2, total extracts (100 μ g). Lane 3, in vitro-translated *cig1* and bacterially expressed *cdc2*. Lanes 4 to 9, immunoprecipitations with anti-*cig1* antiserum (lanes 4 and 6 to 8), with anti-*cig1* preimmune serum (preI) (lane 5), and with anti-*cdc2* antiserum (lane 9). The anti-*cig1* antiserum was incubated in the presence of competing peptide (I+p) (lane 7), or the extract was prepared from a cold-sensitive *nda3*-KM311 strain grown in YEA medium at 36°C and then shifted at 22°C for 8 h (lane 8). Marker sizes (in thousands) are indicated on the left. (B) The Sp202 (*leu1-32*) strain transformed with the pREP1-*cig1* plasmid was grown in minimal medium without thiamine for 16 h. Anti-*cig1* immunoprecipitates were incubated at 25°C for 1 h with PAP (lane 1), with PAP and phosphatase inhibitors (P) (lane 2), and without PAP (control) (lane 3). Immunoprecipitates were then analyzed by immunoblotting with anti-*cig1* antiserum. IgG, immunoglobulin G.

creased compared with the level for a wild-type strain or the same conditional strain grown under permissive conditions. Moreover, the additional *cdc13* was found to be associated with *cdc2*.

The levels of *suc1* and *cdc13* were quantified by immunoprecipitating *suc1* or *cdc13* during a time course experiment (Fig. 4B and C). For this purpose, a strain expressing *suc1* under the control of the *nmt1*-T4 promoter (4) was used. The levels of *suc1* decreased rapidly after thiamine addition, and after 24 h *suc1* was detected at less than 0.1% of the initial levels. In contrast, following thiamine addition an increase in *cdc13* abundance estimated to be approximately ninefold was detected after 24 h. These data show that the cell cycle arrest caused by loss of *suc1* function is correlated with an increase in *cdc2*-*cdc13* kinase activity and also in the *cdc13* protein levels.

***cig1* associates with the *cdc2* kinase.** The experiments reported in the previous section did not allow us to establish whether *suc1* specifically regulates the mitotic *cdc2*-*cdc13* kinase or also has an effect on the activity of other *cdc2*-cyclin complexes. To address this point, we decided to study a *cdc2*-cyclin complex different from *cdc2*-*cdc13* and to investigate the effect of loss of *suc1* function on that complex. For this purpose, the *cig1* cyclin was chosen. An initial biochemical characterization of this cyclin was therefore necessary. A polyclonal antiserum against a peptide representing a unique region of *cig1* (the first 15 N-terminal residues) was generated. Lanes 1 and 2 of Fig. 5A show immunoblots of *cig1* (top panel) and *cdc2* (bottom panel) performed on a total cell extract from an *S. pombe* strain carrying the pREP1-*cig1*-inducible vector, grown in the presence or the absence of thiamine. After 16 h of promoter derepression, two bands with M_r s of 50,000 and 54,000 were detected by the anti-*cig1* antiserum. The faster-migrating band had the same electrophoretic mobility as in vitro-translated *cig1* protein (lane 3). Both bands were recognized by the anti-*cig1* antiserum in immunoprecipitations (lanes 4 to 7). In addition, a coprecipitated band with an M_r of 34,000, recognized by affinity-purified anti-*cdc2* antibodies, was also detected. The specificity of the immunoprecipitation was tested by using preimmune serum or immune serum in the presence of competing antigenic peptide (lanes 5 and 7). The endogenous level of *cig1* was apparently too low to be detected

by our anti-*cig1* antiserum in wild-type asynchronous cells, and the protein also was undetectable in cells lacking *suc1* (data not shown). For this reason, we could not determine whether loss of *suc1* affected the levels of *cig1* protein.

Interestingly, the 54K band could be detected after immunoprecipitation from an *nda3*-KM311 cold-sensitive mutant strain arrested at 20°C for 8 h (Fig. 5, lane 8). This mutant, defective in β -tubulin, when shifted to the restrictive temperature arrests its cycle in midmitosis with condensed chromosomes and a high level of *cdc2* kinase activity (26, 32). The retarded mobility of the *cig1* band found in *nda3* arrested mitotic cells suggested that it could correspond to a phosphorylated form. To test this hypothesis, a *cig1* immunoprecipitation, prepared from a *cig1*-overexpressing strain, was treated with PAP. After this treatment, the electrophoretic mobility of the upper band increased to equal that of the lower band (Fig. 5B, lane 1). A control treatment used in the absence of PAP or in the presence of PAP and phosphatase inhibitors (lanes 2 and 3) confirmed that the change in mobility was due to dephosphorylation rather than to protein degradation. In the *nda3*-KM311 arrested cells, *cdc2* coprecipitated with *cig1*, indicating that the *cdc2*-*cig1* complex might play a role in mitosis. The hyperphosphorylated form of *cig1* was found to associate with *cdc2* in this mutant or in a wild-type strain overexpressing *cig1* (Fig. 5A, lanes 8 and 9). It is possible therefore that either *cig1* becomes rapidly phosphorylated by *cdc2* as soon as the complex forms or its phosphorylation by a yet unknown kinase(s) is a prerequisite for its association with *cdc2*. Further investigation is required to address this point. We then investigated whether the *cdc2*-*cig1* complex had histone H1 kinase activity. We could detect specific phosphorylation of histone H1 after immunoprecipitation of *cig1* from a wild-type strain (Fig. 6A). In the *cig1* overexpressing strain, after induction for 16 h in thiamine-free medium, we could detect a 20-fold increase in the *cig1*-associated histone H1 kinase activity (Fig. 6B). The *cig1*-associated histone H1 kinase activity precipitated from a temperature-sensitive *cdc2* (*cdc2-L7*) strain disappeared after incubation at 37°C, and the temperature sensitivity of the kinase was rescued by the addition of bacterially produced *suc1* prior to the incubation, suggesting that *cdc2* was the *cig1*-associated kinase (data not shown).




FIG. 6. *cig1*-associated histone H1 kinase activity. (A) *cig1*-associated histone H1 kinase activity in a wild-type strain. Anti-*cig1* (α -*cig1*) immunoprecipitates were separated from an extract of the Sp972 (wild-type) strain and assayed for histone H1 kinase activity. Reaction products were analyzed by SDS-PAGE and autoradiography and were quantified by scintillation counting. Lane 1, pre-immune serum (pre-I); lane 2, immune serum (I); lane 3, immune serum in the presence of competing peptide (I+pep). (B) *cig1*-associated histone H1 kinase activity in an *nmt1-cig1* strain. The Sp202 (*leu1-32*) strain transformed with the pREP1-*cig1* plasmid was grown in minimal medium with (lanes 1 to 3) or without (lanes 4 to 6) 4 μ M thiamine for 16 h. Anti-*cig1* immunoprecipitates were assayed for kinase activity, with histone H1 as the substrate. Lanes 1 and 4, preimmune serum; lanes 2 and 5, immune serum; lanes 3 and 6, immune serum in the presence of competing peptide. *cig*-OP, hyperphosphorylated *cig1*.

Activation of *cdc2-cig1* kinase at mitosis and effect of loss of *suc1* function. To investigate the regulation of the *cdc2-cig1* complex during the cell cycle, we first assayed the kinase activity of the complex in conditional mutants of *S. pombe* arrested at different stages of the cell cycle (17). The kinase activity of the mitotic *cdc2-cdc13* complex was also measured for comparison (Fig. 7). In a *cdc10-129* mutant, which arrests in G_1 , the kinase activity level of both complexes was very low, and a similar result was obtained with a *cdc25-22* mutant, which arrests at the G_2/M transition with tyrosine-phosphorylated *cdc2*. In G_1/S -arrested mutants (*cdc20-M10*, *cdc21-M68*, and *cdc22-M45*) or in G_2 -arrested mutants (*cdc1-7* and *cdc6-23*), the kinase activity level of both complexes is higher than that in G_1 but much lower than in the *nda3*-KM311 mutant, which arrests in mitosis with the two complexes showing their maximal level of activity. Note that the *cdc13-117* mutant, which arrests with characteristics of both G_2 and M phases (21), was the only mutant showing a difference between the two activities. While the *cdc2-cig1* activity level in this mutant was higher than that in G_1/S or G_2 mutants, the *cdc2-cdc13* activity level was much lower and was similar to the level found in the *cdc10* mutant. The *cdc13-117* mutant is indeed defective for




FIG. 7. Histone H1 kinase assay from *cdc* mutants. Anti-*cdc13* (α -*cdc13*; upper panel) or anti-*cig1* (α -*cig1*; lower panel) immunoprecipitations were performed with extracts of temperature-sensitive mutants arrested at 36°C for 4 h, with the only exception being the cold-sensitive *nda3*-KM311 mutant that was arrested at 22°C for 8 h. Immunoprecipitates were assayed for histone H1 kinase activity and analyzed by SDS-PAGE and autoradiography. Strains: 1, *cdc1-7*; 6, *cdc6-23*; 10, *cdc10-129*; 13, *cdc13-117*; 20, *cdc20-M10*; 21, *cdc21-M68*; 22, *cdc22-M45*; 25, *cdc25-22*; NDA3, *nda3*-KM311.

the association with *cdc2* (6) and, for this reason, the kinase activity level associated with *cdc13* in this strain is very low. On the other hand, the relatively high kinase activity level associated with *cig1* in the *cdc13* mutant indicates that the anti-*cig1* antiserum detects an active complex distinct from the *cdc2-cdc13* complex. In order to confirm that *cig1* and *cdc13* formed two distinct complexes with *cdc2* at mitosis, an immunodepletion experiment was performed (Fig. 8). After depletion of a mitotic extract with control serum, anti-*cdc13* antiserum, or anti-*cdc2* antiserum, the supernatant was used for immunoprecipitations using antisera against *cig1* or *cdc13* in the presence or the absence of competing peptides. The *cdc2-cdc13* complex, which showed higher kinase activity levels than the *cdc2-cig1* complex (lanes 1 to 4), was quantitatively depleted by the anti-*cdc13* antiserum, while the activity of the *cdc2-cig1* complex was not affected by this depletion (lanes 5 to 8). Depletion with anti-*cdc2* antiserum eliminated both activities, proving that the kinase subunit associated with *cig1* is *cdc2* (lanes 9 to 12).

We then investigated the effect of loss of *suc1* on the *cdc2-cig1* kinase activity. Loss of *suc1* caused an increase in kinase activity of approximately threefold above wild-type levels (Fig. 9). Compared with the effect observed on the *cdc2-cdc13* kinase activity, which in the absence of *suc1* increased about 15-fold above wild-type levels (Fig. 3), the *cdc2-cig1* kinase was relatively little affected by loss of *suc1* function. This difference could reflect the fact that the two complexes are activated at mitosis with different kinetics. In order to examine this possibility, we monitored the kinetics of activation of the *cdc13-cdc2* kinase and of the *cig1-cdc2* kinase after release at the permissive temperature (25°C) of a *cdc25^{ts}* mutant which had been blocked at 37°C for 4 h. During the first 40 min after the release, samples were taken every 10 min in order to monitor precisely the kinetics of activation of the two complexes, while the last three samples were taken at 20-min intervals (Fig. 10). We were not able to detect any significant difference in the kinetics of activation: both complexes reached the maximal activation level (corresponding to an increase of about fivefold above the initial level) after 20 min and declined to the basal level after 60 to 80 min. We conclude therefore that loss of *suc1* function differentially affects the activities of the two mitotic forms of the *cdc2* kinase.




FIG. 8. *cdc2* kinase associated with two different cyclins at mitosis. An extract prepared from an *nda3*-KM311 mutant arrested at 22°C for 8 h was used for three different immunodepletions performed by using a control serum (lanes 1 to 4), an anti-*cdc13* antiserum (lanes 5 to 8), and an anti-*cdc2* antiserum (lanes 9 to 12). In each case, after the first depletion, the supernatant was used for two successive depletions. Immunoprecipitations were performed with the depleted extracts by using either anti-*cig1* (α cig1) or anti-*cdc13* (α cdc13) antiserum in the presence (+) or absence (-) of competing peptide (pep), and then the precipitates were assayed for histone H1 kinase activity.

DISCUSSION

In this study, we have investigated the effect of loss of *suc1* function in *S. pombe* and we have demonstrated the existence of a mitotic complex formed by *cdc2* and the *cig1* cyclin. The effect of loss of *suc1* function on this complex and on the *cdc2*-*cdc13* mitotic complex has been investigated.

We report that in cycling cells, with *suc1* expression under the control of a thiamine-repressible promoter, loss of *suc1* function causes an arrest of the cells with a heterogeneous phenotype and of most of the cells with condensed chromosomes. A previous study performed with germinating spores showed that arrest occurred in cells lacking *suc1* with a heterogeneous morphology and in some cells with condensed chromosomes and a mitotic spindle (32). The significance of the heterogeneity of the phenotype is not clear at present.

By using specific anti-*cig1* antibodies, we have shown that the *cig1* cyclin associates with *cdc2*. The *cdc2*-*cig1* kinase forms a complex which is active at mitosis, and it is distinct from the *cdc2*-*cdc13* complex. We also show that the two complexes are activated at mitosis with the same kinetics. Genetic data have suggested that *cig1* is required in late mitosis for nuclear separation (11). A role for *cig1* for progression through G_1/S has also been proposed (9, 11; however, also see the reference 9 erratum). Our findings suggest a function for *cig1* at mitosis. *cig1* shares the greatest sequence similarity with cyclins CLB3 and CLB4, which have been shown to act in two phases of the *S. cerevisiae* cell cycle, in S and M phases (18, 39). It is possible that *cig1* has a similar function in *S. pombe*, acting both in S phase and M phase, and that other cyclins with redundant functions exist. Further investigation will be required to estab-

lish the actual role of *cig1* in mitosis and in other phases of the cell cycle.

Loss of *suc1* function caused a 15- to 16-fold increase of the *cdc2*-*cdc13* kinase activity but only a 2- to 3-fold increase of the *cdc2*-*cig1* kinase activity over the respective wild-type levels. Since the two complexes are activated with the same kinetics, we propose that *suc1* differentially affects the kinase activities of the two complexes.




FIG. 9. *cig1*-associated histone H1 kinase activity in wild-type and *suc1*-conditional strains. Wild-type (wt) (lane 1) and *suc1*-conditional strains (lanes 2 and 3) were grown in minimal medium with (+) or without (-) 10 μ M thiamine. Extracts were subjected to anti-*cig1* (α -*cig1*) immunoprecipitation (inset), and the immunoprecipitates were assayed for histone H1 kinase activity. sc, *suc1*-conditional strain.




FIG. 10. Activation of the *cig1-cdc2* kinase after the release of a *cdc25-22* arrested mutant. A *cdc25-22* temperature-sensitive mutant was arrested at 36°C for 4 h and released (time zero) by cooling to 25°C quickly in an ice bath. Samples were collected at the indicated times. Immunoprecipitations (shown below the activity graph) were performed with anti-*cig1* (α cig1) and anti-*cdc13* (α cdc13) antisera and assayed for histone H1 kinase activity. Values are expressed as a percentage of the maximum level of kinase activity of each complex.

These and previous findings (32) support the idea that *suc1* is required for M-phase progression. In contrast, experiments with *S. cerevisiae* indicate that Cks1 (the budding yeast *suc1* homolog) is required at the G_1/S and G_2/M transition points, and its loss does not apparently affect the activity of *cdc28* kinase (45). This conclusion is based on the analysis of three temperature-sensitive *cks1* mutant strains, which behave as leaky temperature-sensitive mutants: i.e., the cell cycle is blocked in G_2 when the temperature is shifted to 37°C. However, if the same cells are shifted to an environment with the highest temperature at which they normally grow (38.5°C), the cycle also stops in G_1 . We have not been able to detect an effect on G_1 progression associated with loss of *suc1* function (data not shown). Therefore, *suc1* might differ from Cks1 in this respect. However, it is formally possible that *suc1* has a G_1 function also in *S. pombe* and this cannot be detected by our experimental conditions.

We have been unsuccessful in attempts to isolate a temperature-sensitive mutant of *suc1*, and this might reflect the great stability of the *S. pombe* protein. Another possible interpretation is that the G_1 block reported for *S. cerevisiae* by Tang and Reed (45) is due to a stabilizing function of Cks1 on *cdc28* at a high temperature. In vitro experiments have shown that in *S. pombe* *suc1* has a stabilizing effect on *cdc2^{ts}* mutants at 37°C (6, 29, 32). A stabilizing effect on the wild-type *cdc2* kinase activity has also been observed at this or higher temperatures (3, 6). This observation suggests that at high temperatures loss of *suc1* function affects the stability of *cdc2*, hence affecting all the restriction points at which the *cdc2* function is required. In this

respect, it is not surprising that *suc1* was initially isolated from *S. pombe* as a suppressor of temperature-sensitive strains of *cdc2* defective in their G_1 and G_2 functions (24). A quantitative study of the effect of loss of *CKS1* function on the G_1 and G_2 forms of the *cdc28* kinase in *S. cerevisiae* would be informative. We show that in the absence of *suc1* not only the activity of the *cdc2-cdc13* kinase but also the abundance of the *cdc13* protein increases dramatically (Fig. 4).

Since *suc1* is a component of the *cdc2* complex (8), it is possible that it is required for degradation of the mitotic cyclin *cdc13* and that in its absence cell cycle arrest occurs in mitosis because *cdc13* cannot be degraded. This could be due, for example, to a failure to activate the ubiquitin degradation pathway in the absence of *suc1*. It will be interesting to investigate whether *suc1* is required for cyclin degradation in a reconstituted system in which the molecular components involved in cyclin degradation can be studied more directly.

Alternatively, in the absence of *suc1*, the *cdc2-cdc13* complex might be unable to properly execute mitosis. Crystallization and biochemical studies of Ckshs2 (a human *suc1* homolog) have suggested the existence of dimers and hexamers of *suc1* (35). On the basis of these studies, it has been proposed that *suc1* could have a docking function required for the multimerization of *cdc2-cyclin* heterodimers and that formation of higher order complexes containing multiple *cdc2-cyclin* heterodimers would be essential for proper progression through mitosis (35). If this model is correct, *cdc2-cyclin* multimers could not be assembled in the absence of *suc1*, leading to the activation of a form of *cdc2* kinase which would perform only some of the functions required for proper execution of mitosis. Failure to complete some critical mitotic events could result in the activation of a feedback control mechanism which blocks cyclin degradation and leads to the accumulation of mitotic cyclins. If this model is correct, accumulation of *cdc13* would be not the cause but a consequence of the arrest in M phase. In an *nda3* arrested mutant defective in microtubule polymerization, mitosis cannot be properly completed and this causes a block in cyclin degradation. In those cells, the levels of *cdc13* and *cig1* (Fig. 5) are high and readily detectable. It is interesting that in the absence of *suc1* there is a dramatic increase in the levels of *cdc13*, while we could not detect an increase in the levels of *cig1*. This difference might be important and should be considered in further studies investigating the function of *suc1* and its molecular mechanism of action.

ACKNOWLEDGMENTS

We thank Jacqueline Hayles and Paul Nurse for the generous gift of the diploid strain heterozygous for *suc1* disruption and Mitsuhiro Yanagida for the gift of the *nda3-KM311* strain. Leonardo Brizuela, Paul Clarke, and Tamar Enoch are thanked for critical reading of the manuscript. Randy Johnson is thanked for his help during the preparation of the figures.

REFERENCES

- Alfa, C., J. Hyams, M. McLeod, and E. Warbrik. 1993. Experiments with fission yeast: a laboratory course manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Basi, G. 1993. Regulation of the cell cycle by *p13^{suc1}* in *Schizosaccharomyces pombe*. Ph.D. thesis. European Molecular Biology Laboratory, Heidelberg, Germany.
- Basi, G., and G. Draetta. Unpublished data.
- Basi, G., E. Schmid, and K. Maundrell. 1993. TATA box mutations in the *Schizosaccharomyces pombe nmt1* promoter affect transcription efficiency but not the transcription start point or the thiamine repressibility. *Gene* 123: 131-136.
- Booher, R., and D. Beach. 1988. Involvement of *cdc13+* in mitotic control in *Schizosaccharomyces pombe*: possible interaction of the gene product with microtubules. *EMBO J.* 7:2321-2327.
- Booher, R. N., C. E. Alfa, J. S. Hyams, and D. H. Beach. 1989. The fission

- yeast *cdc2/cdc13/suc1* protein kinase: regulation of catalytic activity and nuclear localization. *Cell* **58**:485–497.
7. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**:248–254.
 8. Brizuela, L., G. Draetta, and D. Beach. 1987. *p13^{suc1}* acts in the fission yeast cell division cycle as a component of the *p34^{cdc2}* protein kinase. *EMBO J.* **6**:3507–3514.
 9. Bueno, A., H. Richardson, S. I. Reed, and P. Russell. 1991. A fission yeast B-type cyclin functioning early in the cell cycle. *Cell* **65**:149–159. (Erratum, *73*:1050, 1993.)
 10. Bueno, A., and P. Russell. 1993. Two fission yeast B-type cyclins, *Cig1* and *Cdc13*, have different functions in mitosis. *Mol. Cell. Biol.* **13**:2286–2297.
 11. Connolly, T., and D. Beach. 1994. Interaction between *Cig1* and *Cig2* B-type cyclins in the fission yeast cell cycle. *Mol. Cell. Biol.* **14**:768–776.
 12. Draetta, G., and D. Beach. 1988. Activation of *cdc2* protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. *Cell* **54**:17–26.
 13. Draetta, G., L. Brizuela, J. Potashkin, and D. Beach. 1987. Identification of *p34* and *p13*, human homologs of the cell cycle regulators of fission yeast encoded by *cdc2+* and *suc1+*. *Cell* **50**:319–325.
 14. Dunphy, W., and J. Newport. 1989. Fission yeast *p13* blocks mitotic activation and tyrosine dephosphorylation of the *Xenopus cdc2* protein kinase. *Cell* **58**:181–191.
 15. Dunphy, W. G., L. Brizuela, D. Beach, and J. Newport. 1988. The *Xenopus cdc2* protein is a component of MPF, a cytoplasmic regulator of mitosis. *Cell* **54**:423–431.
 16. Epstein, C. B., and F. R. Cross. 1993. *CLB5*: a novel B cyclin from budding yeast with a role in S phase. *Genes Dev.* **6**:1695–1706.
 17. Fantes, P. A. 1989. Cell cycle controls, p. 127–204. In A. Nasim, P. Young, and B. F. Johnson (ed.), *Molecular biology of the fission yeast*. Academic Press, San Diego, Calif.
 18. Grandin, N., and S. I. Reed. 1993. Differential function and expression of *Saccharomyces cerevisiae* B-type cyclins in mitosis and meiosis. *Mol. Cell. Biol.* **13**:2113–2125.
 19. Hadwiger, J. A., C. Wittenberg, M. D. Mendenhall, and S. I. Reed. 1989. The *Saccharomyces cerevisiae* *CKS1* gene, a homolog of the *Schizosaccharomyces pombe* *suc1+* gene, encodes a subunit of the *Cdc28* protein kinase complex. *Mol. Cell. Biol.* **9**:2034–2041.
 20. Hadwiger, J. A., C. Wittenberg, H. E. Richardson, M. de Barros Lopes, and S. I. Reed. 1989. A novel family of cyclin homologs that control G1 in yeast. *Proc. Natl. Acad. Sci. USA* **86**:6255–6259.
 21. Hagan, L., J. Hayles, and P. Nurse. 1988. Cloning and sequencing of the cyclin-related *cdc13+* gene and a cytological study of its role in fission yeast mitosis. *J. Cell Sci.* **91**:587–595.
 22. Harlow, E., and D. Lane (ed.). 1988. *Antibodies: a laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
 23. Hayles, J., S. Aves, and P. Nurse. 1986. *suc1* is an essential gene involved in both the cell cycle and growth in fission yeast. *EMBO J.* **5**:3373.
 24. Hayles, J., D. Beach, B. Durkacz, and P. Nurse. 1986. The fission yeast cell cycle control gene *cdc2*: isolation of a sequence *suc1* that suppresses *cdc2* mutant function. *Mol. Gen. Genet.* **202**:291–293.
 25. Hindley, J., and G. A. Phear. 1984. Sequence of the cell division gene *cdc2+* from *Schizosaccharomyces pombe*; patterns of splicing and homology to protein kinases. *Gene* **31**:129–134.
 26. Hiraoka, Y., T. Toda, and M. Yanagida. 1984. The *NDA3* gene of fission yeast encodes beta-tubulin: a cold-sensitive *nda3* mutation reversibly blocks spindle formation and chromosome movement in mitosis. *Cell* **39**:349–358.
 27. Kumagai, A., and W. Dunphy. 1991. The *cdc25* protein controls tyrosine dephosphorylation of the *cdc2* protein in a cell-free system. *Cell* **64**:903–914.
 28. Kuret, J., K. E. Johnson, C. Nicolette, and M. J. Zoller. 1988. Mutagenesis of the regulatory subunit of yeast cAMP-dependent protein kinase. Isolation of site-directed mutants with altered binding affinity for catalytic subunit. *J. Biol. Chem.* **263**:9149–9154.
 29. Marcote, M. J., D. R. Knighton, G. Basi, J. M. Sowadski, P. Brambilla, G. Draetta, and S. S. Taylor. 1993. A three-dimensional model of the *Cdc2* protein kinase: identification of cyclin- and *Suc1*-binding regions and phosphorylation sites. *Mol. Cell. Biol.* **13**:5122–5131.
 30. Matsumoto, T., and D. Beach. 1991. Premature initiation of mitosis in yeast lacking *RCC1* or an interacting GTPase. *Cell* **66**:347–360.
 31. Maundrell, K. 1990. *nmt1* of fission yeast. A highly transcribed gene completely repressed by thiamine. *J. Biol. Chem.* **265**:10857–10864.
 32. Moreno, S., J. Hayles, and P. Nurse. 1989. Regulation of *p34^{cdc2}* protein kinase during mitosis. *Cell* **58**:361–372.
 33. Moreno, S., A. Klar, and P. Nurse. 1991. Molecular genetic analysis of fission yeast *Schizosaccharomyces pombe*. *Methods Enzymol.* **194**:795–826.
 34. Nurse, P., and Y. Bissett. 1981. Genes required for G1 for commitment to cell cycle and in G2 for control of mitosis in fission yeast. *Nature (London)* **292**:558–560.
 35. Parge, H. E., A. S. Arvai, D. J. Murtari, S. I. Reed, and J. A. Tainer. 1993. Human *ckshs2* atomic structure: a role of its hexameric assembly in cell cycle control. *Science* **262**:387–395.
 36. Piggot, J., R. Rai, and B. Carter. 1982. A bifunctional gene product involved in two phases of the cell cycle. *Nature (London)* **298**:391–393.
 37. Pines, J., and T. Hunter. 1991. Cyclin-dependent kinases: a new cell cycle motif? *Trends Cell Biol.* **1**:117–121.
 38. Riabowol, K., G. Draetta, L. Brizuela, D. Vandre, and D. Beach. 1989. The *cdc2* kinase is a nuclear protein that is essential for mitosis in mammalian cells. *Cell* **57**:393–401.
 39. Richardson, H., D. J. Lew, M. Henze, K. Sugimoto, and S. Reed. 1992. Cyclin-B homologs in *Saccharomyces cerevisiae* function in S phase and in G2. *Genes Dev.* **6**:2021–2034.
 40. Richardson, H., K. Wittenberg, F. Cross, and S. Reed. 1989. An essential G1 function for cyclin-like proteins in yeast. *Cell* **59**:1127–1133.
 41. Richardson, H. E., C. S. Stueland, J. Thomas, P. Russell, and S. I. Reed. 1990. Human cDNAs encoding homologs of the small *p34^{CDC28/cdc2}*-associated protein in *Saccharomyces cerevisiae* and *Schizosaccharomyces pombe*. *Genes Dev.* **4**:1332–1334.
 42. Sazer, S., and S. Sherwood. 1990. Mitochondrial growth and DNA synthesis occur in the absence of nuclear DNA replication in fission yeast. *J. Cell Sci.* **97**:509–516.
 43. Schwob, E., and K. Nasmyth. 1993. *CLB5* and *CLB6*, a new pair of B cyclins involved in DNA replication in *Saccharomyces cerevisiae*. *Genes Dev.* **7**:1160–1175.
 44. Sherr, C. J. 1993. Mammalian G1 cyclins. *Cell* **73**:1059–1065.
 45. Tang, Y., and S. I. Reed. 1993. The Cdk-associated protein *Cks1* functions both in G1 and G2 in *Saccharomyces cerevisiae*. *Genes Dev.* **7**:822–832.